Janux Therapeutics, Inc.
US ˙ NasdaqGM ˙ US47103J1051

Introduction

This page provides a comprehensive analysis of the known insider trading history of Avalon Ventures XI, L.P.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Avalon Ventures XI, L.P. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:JANX / Janux Therapeutics, Inc. 10% Owner 2,115,373
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Avalon Ventures XI, L.P.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases JANX / Janux Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in JANX / Janux Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2023-11-13 JANX Avalon Ventures XI, L.P. 849,854 5.8700 849,854 5.8700 4,988,643 172 64.7800 50,064,900 1,003.58
2021-06-15 JANX Avalon Ventures XI, L.P. 629,411 17.0000 629,411 17.0000 10,699,987

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

JANX / Janux Therapeutics, Inc. Insider Trades
Insider Sales JANX / Janux Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in JANX / Janux Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2024-10-18 JANX Avalon Ventures XI, L.P. 102,732 50.3000 102,732 50.3000 5,167,420 293 22.5800 -2,847,730 -55.11
2024-10-18 JANX Avalon Ventures XI, L.P. 19,900 50.3000 19,900 50.3000 1,000,970
2024-10-18 JANX Avalon Ventures XI, L.P. 104,892 50.3000 104,892 50.3000 5,276,068
2024-10-18 JANX Avalon Ventures XI, L.P. 15,462 51.1800 15,462 51.1800 791,345
2024-10-18 JANX Avalon Ventures XI, L.P. 2,995 51.1800 2,995 51.1800 153,284
2024-10-18 JANX Avalon Ventures XI, L.P. 15,788 51.1800 15,788 51.1800 808,030
2024-10-18 JANX Avalon Ventures XI, L.P. 541,824 44.7500 541,824 44.7500 24,246,624
2024-10-18 JANX Avalon Ventures XI, L.P. 104,957 44.7500 104,957 44.7500 4,696,826
2024-10-18 JANX Avalon Ventures XI, L.P. 553,219 44.7500 553,219 44.7500 24,756,550
2024-10-17 JANX Avalon Ventures XI, L.P. 1,843 50.0200 1,843 50.0200 92,187
2024-10-16 JANX Avalon Ventures XI, L.P. 60,179 49.6900 60,179 49.6900 2,990,295
2024-10-16 JANX Avalon Ventures XI, L.P. 11,657 49.6900 11,657 49.6900 579,236
2024-10-16 JANX Avalon Ventures XI, L.P. 61,445 49.6900 61,445 49.6900 3,053,202
2024-10-16 JANX Avalon Ventures XI, L.P. 29,474 50.6100 29,474 50.6100 1,491,679
2024-10-16 JANX Avalon Ventures XI, L.P. 5,710 50.6100 5,710 50.6100 288,983
2024-10-16 JANX Avalon Ventures XI, L.P. 30,094 50.6100 30,094 50.6100 1,523,057
2024-10-16 JANX Avalon Ventures XI, L.P. 10,957 50.8000 10,957 50.8000 556,616
2024-09-30 JANX Avalon Ventures XI, L.P. 958 46.2400 958 46.2400 44,298
2024-09-27 JANX Avalon Ventures XI, L.P. 45,894 46.4200 45,894 46.4200 2,130,399
2024-09-27 JANX Avalon Ventures XI, L.P. 8,894 46.4200 8,894 46.4200 412,859
2024-09-27 JANX Avalon Ventures XI, L.P. 46,861 46.4200 46,861 46.4200 2,175,288
2024-09-27 JANX Avalon Ventures XI, L.P. 1,511 47.7400 1,511 47.7400 72,135
2024-09-27 JANX Avalon Ventures XI, L.P. 293 47.7400 293 47.7400 13,988
2024-09-27 JANX Avalon Ventures XI, L.P. 1,542 47.7400 1,542 47.7400 73,615
2024-09-27 JANX Avalon Ventures XI, L.P. 1,826 46.1900 1,826 46.1900 84,343
2024-09-26 JANX Avalon Ventures XI, L.P. 49,497 46.7800 49,497 46.7800 2,315,470
2024-09-26 JANX Avalon Ventures XI, L.P. 9,592 46.7800 9,592 46.7800 448,714
2024-09-26 JANX Avalon Ventures XI, L.P. 50,539 46.7800 50,539 46.7800 2,364,214
2024-09-26 JANX Avalon Ventures XI, L.P. 40,803 47.7700 40,803 47.7700 1,949,159
2024-09-26 JANX Avalon Ventures XI, L.P. 7,908 47.7700 7,908 47.7700 377,765
2024-09-26 JANX Avalon Ventures XI, L.P. 41,661 47.7700 41,661 47.7700 1,990,146
2024-09-12 JANX Avalon Ventures XI, L.P. 158,031 47.0000 158,031 47.0000 7,427,457
2024-09-12 JANX Avalon Ventures XI, L.P. 30,613 47.0000 30,613 47.0000 1,438,811
2024-09-12 JANX Avalon Ventures XI, L.P. 161,356 47.0000 161,356 47.0000 7,583,732
2024-09-10 JANX Avalon Ventures XI, L.P. 11,319 46.1300 11,319 46.1300 522,145
2024-09-10 JANX Avalon Ventures XI, L.P. 2,193 46.1300 2,193 46.1300 101,163
2024-09-10 JANX Avalon Ventures XI, L.P. 11,557 46.1300 11,557 46.1300 533,124
2024-09-10 JANX Avalon Ventures XI, L.P. 34,326 46.6600 34,326 46.6600 1,601,651
2024-09-10 JANX Avalon Ventures XI, L.P. 6,649 46.6600 6,649 46.6600 310,242
2024-09-10 JANX Avalon Ventures XI, L.P. 35,047 46.6600 35,047 46.6600 1,635,293
2024-09-09 JANX Avalon Ventures XI, L.P. 2,182 42.3300 2,182 42.3300 92,364
2024-09-06 JANX Avalon Ventures XI, L.P. 108,365 42.0000 108,365 42.0000 4,551,330
2024-09-06 JANX Avalon Ventures XI, L.P. 20,991 42.0000 20,991 42.0000 881,622
2024-09-06 JANX Avalon Ventures XI, L.P. 110,644 42.0000 110,644 42.0000 4,647,048
2024-06-03 JANX Avalon Ventures XI, L.P. 677,279 54.7500 677,279 54.7500 37,081,025
2024-06-03 JANX Avalon Ventures XI, L.P. 131,196 54.7500 131,196 54.7500 7,182,981
2024-06-03 JANX Avalon Ventures XI, L.P. 691,525 54.7500 691,525 54.7500 37,860,994

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

JANX / Janux Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Avalon Ventures XI, L.P. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2024-10-18 2024-10-18 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -553,219 2,115,373 -20.73 44.75 -24,756,550 94,662,942
2024-10-18 2024-10-18 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -104,957 401,321 -20.73 44.75 -4,696,826 17,959,115
2024-10-18 2024-10-18 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -541,824 2,071,799 -20.73 44.75 -24,246,624 92,713,005
2024-10-18 2024-10-18 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -15,788 2,668,592 -0.59 51.18 -808,030 136,578,539
2024-10-18 2024-10-18 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -2,995 506,278 -0.59 51.18 -153,284 25,911,308
2024-10-18 2024-10-18 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -15,462 2,613,623 -0.59 51.18 -791,345 133,765,225
2024-10-18 2024-10-18 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -104,892 2,684,380 -3.76 50.30 -5,276,068 135,024,314
2024-10-18 2024-10-18 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -19,900 509,273 -3.76 50.30 -1,000,970 25,616,432
2024-10-18 2024-10-18 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -102,732 2,629,085 -3.76 50.30 -5,167,420 132,242,976
2024-10-18 2024-10-17 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -1,843 6,371 -22.44 50.02 -92,187 318,677
2024-10-18 2024-10-17 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 237 8,214 2.97 39.80 9,433 326,917
2024-10-18 2024-10-17 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 348 7,977 4.56 13.22 4,601 105,456
2024-10-18 2024-10-17 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 348 7,629 4.78 10.73 3,734 81,859
2024-10-18 2024-10-17 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 836 7,281 12.97 17.00 14,212 123,777
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -10,957 6,445 -62.96 50.80 -556,616 327,406
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 1,407 17,402 8.80 39.80 55,999 692,600
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 2,070 15,995 14.87 13.22 27,365 211,454
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 2,070 13,925 17.46 10.73 22,211 149,415
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 4,968 11,855 72.14 17.00 84,456 201,535
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -30,094 2,789,272 -1.07 50.61 -1,523,057 141,165,056
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -5,710 529,173 -1.07 50.61 -288,983 26,781,446
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -29,474 2,731,817 -1.07 50.61 -1,491,679 138,257,258
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -61,445 2,819,366 -2.13 49.69 -3,053,202 140,094,297
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -11,657 534,883 -2.13 49.69 -579,236 26,578,336
2024-10-18 2024-10-16 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -60,179 2,761,291 -2.13 49.69 -2,990,295 137,208,550
2024-09-30 2024-09-30 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -958 6,887 -12.21 46.24 -44,298 318,455
2024-09-30 2024-09-30 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 123 7,845 1.59 39.80 4,895 312,231
2024-09-30 2024-09-30 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 181 7,722 2.40 13.22 2,393 102,085
2024-09-30 2024-09-30 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 181 7,541 2.46 10.73 1,942 80,915
2024-09-30 2024-09-30 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 434 7,360 6.27 17.00 7,378 125,120
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -1,826 6,926 -20.86 46.19 -84,343 319,912
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 234 8,752 2.75 39.80 9,313 348,330
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 345 8,518 4.22 13.22 4,561 112,608
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 345 8,173 4.41 10.73 3,702 87,696
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 828 7,828 11.83 17.00 14,076 133,076
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -1,542 2,880,811 -0.05 47.74 -73,615 137,529,917
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -293 546,540 -0.05 47.74 -13,988 26,091,820
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -1,511 2,821,470 -0.05 47.74 -72,135 134,696,978
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -46,861 2,882,353 -1.60 46.42 -2,175,288 133,798,826
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -8,894 546,833 -1.60 46.42 -412,859 25,383,988
2024-09-30 2024-09-27 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -45,894 2,822,981 -1.60 46.42 -2,130,399 131,042,778
2024-09-30 2024-09-26 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -41,661 2,929,214 -1.40 47.77 -1,990,146 139,928,553
2024-09-30 2024-09-26 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -7,908 555,727 -1.40 47.77 -377,765 26,547,079
2024-09-30 2024-09-26 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -40,803 2,868,875 -1.40 47.77 -1,949,159 137,046,159
2024-09-30 2024-09-26 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -50,539 2,970,875 -1.67 46.78 -2,364,214 138,977,532
2024-09-30 2024-09-26 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -9,592 563,635 -1.67 46.78 -448,714 26,366,845
2024-09-30 2024-09-26 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -49,497 2,909,678 -1.67 46.78 -2,315,470 136,114,737
2024-09-12 2024-09-12 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -161,356 3,021,414 -5.07 47.00 -7,583,732 142,006,458
2024-09-12 2024-09-12 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -30,613 573,227 -5.07 47.00 -1,438,811 26,941,669
2024-09-12 2024-09-12 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -158,031 2,959,175 -5.07 47.00 -7,427,457 139,081,225
2024-09-12 2024-09-10 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -35,047 3,182,770 -1.09 46.66 -1,635,293 148,508,048
2024-09-12 2024-09-10 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -6,649 603,840 -1.09 46.66 -310,242 28,175,174
2024-09-12 2024-09-10 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -34,326 3,117,206 -1.09 46.66 -1,601,651 145,448,832
2024-09-12 2024-09-10 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -11,557 3,217,817 -0.36 46.13 -533,124 148,437,898
2024-09-12 2024-09-10 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -2,193 610,489 -0.36 46.13 -101,163 28,161,858
2024-09-12 2024-09-10 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -11,319 3,151,532 -0.36 46.13 -522,145 145,380,171
2024-09-10 2024-09-09 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -2,182 7,000 -23.76 42.33 -92,364 296,310
2024-09-10 2024-09-09 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 277 9,182 3.11 39.80 11,025 365,444
2024-09-10 2024-09-09 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 414 8,905 4.88 13.22 5,473 117,724
2024-09-10 2024-09-09 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 414 8,491 5.13 10.73 4,442 91,108
2024-09-10 2024-09-09 4 JANX Janux Therapeutics, Inc.
Common Stock 		M - Exercise 994 8,077 14.03 17.00 16,898 137,309
2024-09-10 2024-09-06 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -110,644 3,229,374 -3.31 42.00 -4,647,048 135,633,708
2024-09-10 2024-09-06 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -20,991 612,682 -3.31 42.00 -881,622 25,732,644
2024-09-10 2024-09-06 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -108,365 3,162,851 -3.31 42.00 -4,551,330 132,839,742
2024-06-05 2024-06-03 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -691,525 3,340,018 -17.15 54.75 -37,860,994 182,865,986
2024-06-05 2024-06-03 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -131,196 633,673 -17.15 54.75 -7,182,981 34,693,597
2024-06-05 2024-06-03 4 JANX Janux Therapeutics, Inc.
Common Stock 		S - Sale -677,279 3,271,216 -17.15 54.75 -37,081,025 179,099,076
2024-03-04 2024-02-29 4 JANX Janux Therapeutics, Inc.
Common Stock 		J - Other -1,700 0 -100.00
2024-03-04 2024-02-29 4 JANX Janux Therapeutics, Inc.
Common Stock 		J - Other 1,700 1,700
2024-03-04 2024-02-29 4 JANX Janux Therapeutics, Inc.
Common Stock 		J - Other -84,985 764,869 -10.00
2024-03-04 2024-02-29 4 JANX Janux Therapeutics, Inc.
Common Stock 		J - Other -31,456 0 -100.00
2024-03-04 2024-02-29 4 JANX Janux Therapeutics, Inc.
Common Stock 		J - Other 31,456 31,456
2024-03-04 2024-02-29 4 JANX Janux Therapeutics, Inc.
Common Stock 		J - Other -447,949 4,031,543 -10.00
2024-03-04 2024-02-29 4 JANX Janux Therapeutics, Inc.
Common Stock 		J - Other -11,388 0 -100.00
2024-03-04 2024-02-29 4 JANX Janux Therapeutics, Inc.
Common Stock 		J - Other 11,388 11,388
2024-03-04 2024-02-29 4 JANX Janux Therapeutics, Inc.
Common Stock 		J - Other -438,722 3,948,495 -10.00
2023-11-13 2023-11-13 4 JANX Janux Therapeutics, Inc.
Common Stock 		P - Purchase 849,854 849,854 5.87 4,988,643 4,988,643
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Series B Convertible Preferred Stock 		C - Conversion -900,264 0 -100.00
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Series A Convertible Preferred Stock 		C - Conversion -2,105,264 0 -100.00
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Series A Convertible Preferred Stock 		C - Conversion -526,316 0 -100.00
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Series Seed 2 Convertible Preferred Stock 		C - Conversion -1,859,634 0 -100.00
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Series Seed Convertible Preferred Stock 		C - Conversion -888,888 0 -100.00
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock 		P - Purchase 629,411 4,479,492 16.35 17.00 10,699,987 76,151,364
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock 		C - Conversion 1,153,238 3,850,081 42.76
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock 		C - Conversion 2,696,843 2,696,843
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock 		C - Conversion 674,211 4,387,217 18.16
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock 		C - Conversion 2,382,191 3,713,006 179.00
2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock 		C - Conversion 1,138,665 1,330,815 592.59
2021-06-10 3 JANX Janux Therapeutics, Inc.
Common Stock 		192,150
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)